Kupando GmbH
Angelika Vlachou is an experienced professional currently serving as a Board Member at GQ Bio Therapeutics and smartbax, as well as a Partner at High-Tech Gründerfonds since July 2021. With a background in interim management and consulting for Biotech, MedTech, and Pharma companies, Angelika Vlachou specializes in financial and strategic planning, business development, and market entry strategies. Ongoing board memberships include faCellitate, Kupando GmbH, and past roles at Caterna and 4TEEN4 Pharmaceuticals GmbH. Angelika Vlachou holds a PhD in Medical Virology and Molecular Biology from Justus-Liebig-Universität Gießen, where the final grade was “summa cum laude,” as well as an MBA in BioMedTech from the University of Potsdam.
This person is not in the org chart
This person is not in any teams
Kupando GmbH
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.